AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02085681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-medicine
Description: Patients at the diabetes clinics will be subjected to non-mydriatic retinal imaging and the images will be transferred to the eye hospital via internet using a specified software - Aravind Diabetic Retinopathy Evaluation Software (ADRES) that enables a retinal specialist to read and grad the image and send the feedback immediately to the diabetes clinic. Based on the presence or absence of DR the patients will be referred to the eye hospital for detailed retinal examination.
Study NCT02085681 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional referral
Description: All eligible patients in the conventional arm will be counselled on the importance of eye screening and will be referred to the eye hospital
Study NCT00270361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nesiritide
Study NCT00270361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: usual long term cardiac medications
Study NCT02087436 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taperloc Complete Microplasty
Description: Taperloc Complete Microplsty cementless stem is designed to transmit load to the proximal femur, thereby preserving bone density, and preventing long term instability and loosening secondary to proximal bone resorption.
Study NCT02087436 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taperloc Complete Standard
Description: Taperloc Complete Standard is designed after the philosophy of a flat tapered wedge. It has evolved to incorporate the Reduced Distal and Microplasty stems to better address all patient anatomies, and facilitate multiple surgical techniques.
Study NCT03615781 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two week's arm - surgery
Description: The investigators perform a surgical drainage of the infection along with the complete removal of the infected orthopedic implant.
Study NCT03615781 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Four week's arm - surgery
Description: The investigators perform a surgical drainage of the infection along with the complete removal of the infected orthopedic implant.
Study NCT03615781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Two week's arm - drugs
Description: After the surgical implant removal, the investigators prescribe a total of 2 weeks of systemic targeted antibiotic therapy against the causative pathogen(s), of which one week is recommended to be intravenously.
Study NCT03615781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Four week's arm - drugs
Description: After the surgical implant removal, the investigators prescribe a total of 4 weeks of systemic targeted antibiotic therapy against the causative pathogen(s), of which one week is recommended to be intravenously.
Study NCT00339690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MITE-T-FASTtest kit
Description: The primary objective of this randomized intervention trial is to determine if the use of an inhome test kit, as an adjunct to education, results in greater reductions in dust mite allergen levels than the use of educational materials alone.
Study NCT06684912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise
Description: The number of bouts of exercise-recovery for each participant was tailored to achieve the desired EE. For example, a participant with a peak oxygen uptake (V̇O2) peak of 30 mL.kg-1.min-1, weighing 80 kg, would need 6 bouts to match the target EE, assuming 1L of O2 uptake equals 5 kcal.
Study NCT06684912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate continuous exercise
Description: Energy expenditure of exercise conditions (HIIE and MICE) were matched for energy expenditure. A participant with a V̇O2 peak of 30 mL.kg-1.min-1, weighing 80 kg, would need 6 bouts to match the target EE, assuming 1L of O2 uptake equals 5 kcal.
Study NCT00294099 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide
Description: Aluminum hydroxide adjuvant.
Study NCT04194320 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound (US) guided supraclavicular brachial plexus block
Description: Using 8 mg dexamethasone or 10 mg nalbuphine as adjuvants to (Lidocaine 2% + bupivacaine 0.5% 1:1 mixture) in ultrasound (US) guided supraclavicular brachial plexus block
Study NCT04194320 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound (US) guided supraclavicular brachial plexus block
Description: Using 8 mg dexamethasone or 10 mg nalbuphine as adjuvants to (Lidocaine 2% + bupivacaine 0.5% 1:1 mixture) in ultrasound (US) guided supraclavicular brachial plexus block
Study NCT00294099 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)
Description: Inactivated monovalent subvirion influenza H5N1 vaccine. Supplied in 0.5 mL unit dose vials as a sterile solution for IM injection. Dosages: 45 mcg, 15 mcg, 7.5, mcg, or 3.75 mcg administered with or without aluminum hydroxide adjuvant on Days 0 and 28.
Study NCT01059032 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Using a 3 dimentional post processing filter
Description: Using a 3 dimentional post processing filter
Study NCT04531371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine injection
Description: post surgical agitation prophylaxis
Study NCT04531371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine injection
Description: post surgical agitation prophylaxis
Study NCT02419482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4x4 minutes high intensity interval training
Description: Treadmill running/walking with 10 minutes varm-up at 60-70% of maximum heart rate, 4x4 minute intervals at 90-95% of maximum heart rate separated by 3-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
Study NCT02419482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10x1 minute high intensity interval training
Description: Treadmill running/walking with 10 minutes varm-up at 60-70% of maximum heart rate, ten 1-minute intervals at maximal intensity (that can be performed for one minute), separated by 1-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
Study NCT00672971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4% dimethicone foam
Description: The dimethicone foam is applied to dry hair and left on the hair for approximately 15 minutes. The product is then removed by washing the hair with baby shampoo. The foam is applied two time, separated by an interval of 7-9 days.
Study NCT00672971 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1% permethrin
Description: Nix® Cream Rinse is applied as indicated on the product labeling. The cream rinse is applied to wet hair and left on the hair for 10 minutes. The hair is then rinsed with tepid water to remove the product, toweled dry, and combed with a detangling comb. The product is applied two times, separated by an interval of 7-9 days.
Study NCT04266691 — intervention group
Intervention type: OTHER
Intervention: nonIntervention
Description: nonIntervention
Study NCT02935959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nebulized ketamine
Description: Drugs will be prepared in 3 mL of saline 0.9% before administration by a standard hospital jet nebulizer via a mouthpiece, with a continuous flow of 100% oxygen at 6 L/min for 10 to 15 minutes (30 minutes before GA). Treatment will be stopped when the nebulizer began to sputter.
Study NCT02935959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nebulized Dexmedetomidine
Study NCT02935959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nebulized midazolam
Study NCT01339910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine and Busulfan
Description: (Flu/Bu)~* Fludarabine: 30 mg/m\^2/day on Days -6 to -2 (total dose of 150 mg/m\^2)~* Busulfan: 4 mg/kg/day PO or 3.2 mg/kg/day (total dose of 8 mg/kg or 6.4 mg/kg, respectively) on Days -5 to -4
Study NCT01339910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine and Melphalan
Description: (Flu/Mel)~* Fludarabine: 30 mg/m\^2/day on Days -5 to -2 (total dose of 120 mg/m\^2)~* Melphalan: 140 mg/m\^2 on Day -2
Study NCT01339910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan and Fludarabine
Description: (Bu/Flu)~* Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or mg/m\^2/day with Bu Css 900±100 ng/mL (total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m\^2, respectively) on Days -5 to -2~* Fludarabine: 30 mg/m\^2/day on Days -5 to -2: Flu (total dose of 120 mg/m\^2)
Study NCT01339910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan and Cyclophosphamide
Description: (Bu/Cy)~* Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or 130 mg/m\^2/day with Bu Css 900 ± 100 ng/mL (total dose of 16 mg/kg or 12.8 mg/kg or 520 mg/m\^2, respectively) on Days -7 to -4~* Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)
Study NCT01339910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide and Total Body Irradiation
Description: (Cy/TBI)~* TBI: 1200-1420 cGy on Days -7 to -4~* Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)
Study NCT01775761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 1
Description: A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
Study NCT01775761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2
Description: A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
Study NCT01775761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 3
Description: A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
Study NCT02752776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab was used as commercially available PFS of 150 mg. Patients received PFS at the site and were instructed to administer Secukinumab as needed (300 mg each application).
Study NCT00317499 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01841762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Macitentan tablet, dose of 10 mg, once daily
Study NCT03659175 — intervention group
Intervention type: OTHER
Intervention: SIBO
Description: SIBO: Small intestinal bacterial overgrowth, refers to a bacterial overgrowth due to organic or functional stasis in small intestine, leading to the change in number or types of bacteria in small intestine.
Study NCT01812317 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forearm Vascular Study
Description: Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
Study NCT01812317 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Forearm Vascular Study
Description: Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
Study NCT01812317 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Badimon Chamber Study
Description: Ex-vivo assessment of thrombus formation using the Badimon Chamber
Study NCT01812317 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Badimon Chamber Study
Description: Ex-vivo assessment of thrombus formation using the Badimon Chamber
Study NCT03449654 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Liraglutide
Description: Liraglutid
Study NCT03449654 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo (for liraglutide)
Description: Placebo (for liraglutide)
Study NCT02050217 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurally Adjusted Ventilatory Assist
Study NCT00730795 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's candidate Mycobacterium tuberculosis vaccine 692342
Description: Intramuscular injection, 3 doses at 0, 1, 2 months Different antigen doses (low and high)
Study NCT00795080 — intervention group
Intervention type: PROCEDURE
Intervention: Dynamic cervical MRI scans
Description: Serial MRI examination with the neck in flexion and extension to document changes in the cord compression and cerebral spinal fluid (CSF)
Study NCT02918474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: Use decision making tool
Study NCT02918474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02355184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 140 350mg weekly SQ injection.
Description: CCR5 Antagonist
Study NCT00217893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: One-on-one behavioral counseling with pre-teen child; 8 to 10 weekly or bi-weekly sessions; focus on identifying sources of exposure to ETS and means to avoid exposure; goal-setting, role-playing, monitoring progress, feedback includes reported info and urine cotinine level.
Study NCT00217893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Urine Cotinine Feedback
Description: Urine collected from child at each weekly/bi-weekly counseling session; cotinine level discussed at subsequent session.
Study NCT00217893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingent Incentives
Description: Child earns small prizes for on-task behavior in sessions, plus earns tokens redeemable for other prizes based on reduction in ETS exposure (reported and cotinine level).
Study NCT00217893 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual education program
Description: Participants will receive the usual education about ETS.
Study NCT03095560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRVANA
Description: Nirvana is the first device based on optoelectronic infrared sensors, though which the patient can simply interact through his movements. The rehabilitation exercises with audio-visual stimuli and feedback involve the perceptual-cognitive skills of patients, resulting in a motivational training. Several modes and increasing levels of difficulty characterize each exercise, so the therapist can use a pre-defined rehabilitative solution or new ones, according to patient's needs. The results achieved during rehabilitation allow the therapist to evaluate the patient's actual progress, and then to modify the rehabilitation program. The system is connected to a projector or a big screen (put in front of the patient), reproducing an interactive series of exercises (for trunk, upper and lower limbs, and cognition), thanks to an infrared video camera analyzing the patient's movements, it creates interactivity.
Study NCT03126162 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: InstilIing normal saline into bladder
Description: Backfilling the bladder with 200 mL of normal saline immediately postoperatively, prior to foley catheter removal, after same-day total laparoscopic hysterectomy can potentially increase time to first spontaneous void and time to discharge.
Study NCT03126162 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Removal of foley catheter
Description: Removal of the foley catheter is routinely performed after same-day laparoscopic hysterectomy
Study NCT03126162 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Removal of foley catheter
Description: Removal of the foley catheter is routinely performed after same-day laparoscopic hysterectomy
Study NCT03706430 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse CO-Oximeter sensor
Description: Investigational Pulse CO-Oximeter sensor will measure hemoglobin (SpHb), Pulse Rate (PR), Perfusion Index (Pi), Methemoglobin (SpMet), Pleth Variability Index (PVi), RPVi, etc.
Study NCT03348930 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tolcapone 200 MG
Description: All eligible study subjects will go through a 2-week treatment phase during which they will begin tolcapone at 100mg twice a day.
Study NCT03348930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone 200 MG
Description: All eligible study subjects will go through a 2-week treatment phase during which they will begin tolcapone at 100mg twice a day.
Study NCT04525768 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: JAK2 mutation test
Description: Patients with portal caver cavernoma will be divided into two groups by the result of JAK2 mutation test
Study NCT02475265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol 0.045 mg/levonorgestrel 0.015mg
Study NCT03148860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: subjects will receive once weekly 15 mg (3 capsules) MTX
Study NCT03148860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: subject will receive Ustekinumab open-label over a treatment period of 52 weeks
Study NCT03148860 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ustekinumab
Description: subject will receive Ustekinumab open-label over a treatment period of 52 weeks
Study NCT00961025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229
Description: single dose study : DA-1229 1.25,2.5,5,10,20,40,60mg~multiple dose study : DA-1229 5,10,20,40mg
Study NCT00961025 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT00003137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT01511796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: upper limb rehabiliation
Description: 3 months upper rehabilation (twice a week) and then 3 more months upper limb rehabitation ( twice a week)
Study NCT02013596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEAS pretreatment
Description: Electric stimulation was given through electrode attached to specific acupoints for 30mins before anesthesia induction
Study NCT02013596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEAS treatment
Description: Transcutaneous Electrical Acupoint Stimulation was given to the patient at the same time of the start of anesthesia induction for 30mins
Study NCT03148860 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subjects will receive once weekly 3 capsules PLC to MTX
Study NCT04678921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ210001
Description: human anti-C5aR monoclonal antibody
Study NCT04418128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nafamostat Mesylate
Description: The Nafamostat mesilate group received continuous intravenous infusion of 0.1-0.2 mg/kg/h of nafamostat mesilate mixed with 5% DW.
Study NCT03502070 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: One dose (4 capsules) of placebo
Study NCT03502070 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Tobi Podhaler
Description: The placebo capsule has to be released from the blister card and inserted into the Podhaler device. The device is then actuated and the study drug is inhaled according to the instructions for use
Study NCT00482677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: temozolomide
Description: Temozolomide (concurrent with radiation) 75 mg/m2 PO 3 weeks once a day, daily, from the first day to the last day of radiotherapy, but for no longer than 28 days, and then adjuvantly for up to 12 cycles (150 mg/m2 for the first 5 days of each cycle). Adjuvant TMZ may be escalated to 200mg/m2 in C2 onward if appropriate.
Study NCT00482677 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: DNA methylation analysis
Description: A stratified log-rank test, adjusting for the stratification factors (except centre) plus MGMT promoter methylation status, will be used as the primary method to compare the overall survival between the two arms
Study NCT00482677 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: prior to randomization until end of study
Study NCT02098018 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Program 2
Description: A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
Study NCT00482677 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: Short course radiotherapy
Study NCT02098018 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Program 1
Description: A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
Study NCT01609816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Patients receive dasatinib PO every day (QD) for 6 months.
Study NCT00228696 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: none, screening only
Description: Screening protocol with no intervention
Study NCT00508443 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Three radiation treatments guided by the CT-on-Rails or Trilogy procedure over a period of 2 weeks. Participants prescribed to receive 9 Gy x 3 so that a peripheral dose of 27 Gy is given to the tumor.